The GOG Foundation (GOG) is an independent, non-profit clinical research organization focused on improving outcomes in gynecologic cancers, including ovarian, endometrial, cervical, and vulvar malignancies. The foundation advances patient care by designing, sponsoring, and conducting multi-center clinical trials across academic and community hospitals in the United States and internationally.
GOG provides scientific leadership and operational infrastructure for phase I–III studies, including protocol development, site activation and monitoring, data management, and analysis. It collaborates with investigators, cooperative groups, and biopharmaceutical companies to evaluate new therapeutics and treatment strategies, and disseminates evidence that informs standards of care and clinical guidelines in gynecologic oncology.
FDA grants Breakthrough Therapy status to sofetabart mipitecan for platinum-resistant ovarian cancer, based on promising Phase 1 results. Phase 3 trial underway.
